Tag: plaque psoriasis

1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in the sonelokimab groups than in the placebo group. 2. No dose-response associations with toxicity were apparent for the sonelokimab groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Sonelokimab is a novel trivalent nanobody comprised of...
1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in the sonelokimab groups than in the placebo group. 2. No dose-response associations with toxicity were apparent for the sonelokimab groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Sonelokimab is a novel trivalent...
1. Bimekizumab treatment was shown to be noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab treatment. 2. Bimekizumab treatment was shown to have a higher risk for oral candidiasis infection compared to secukinumab treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: The pathology of psoriasis involves the...
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of PASI90 and IGA response. 2. The safety profile of Bimekizumab was overall mild and similar to current treatment option ustekinumab Evidence Rating Level: 1 (Excellent) Study Rundown: Plaque psoriasis is a chronic...
1. 91% of patients receiving bimekizumab 320 mg every 4 weeks achieved ≥ 90% improvement from baseline in the Psoriasis Area Severity Index (PASI90) compared to 1% receiving placebo. 2. After achieving PASI90 at week 16, bimekizumab response was maintained through week 56 in both dosing schedules (every 4 weeks...
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial The ideal surgical excision margin for patients with thick (>2 mm) localized cutaneous melanomas is unclear, where the risk of recurrence must be weighed against excess morbidity resulting from...